


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) The compounds of general A compound having the formula (1)



in which:


- (a) represents a single bond or a double bond;
- W represents a CH, CH₂, CHCH₃, CCH₃ or C(CH₃)₂ group, a C(CH₂)₂ group (i.e. a carbon atom bearing two methylene groups linked together so as to form a spiro-cyclopropane unit) or a C(CH₂)₃ group (i.e. a carbon atom bearing two methylene groups linked to another methylene group so as to form a spiro-cyclobutane unit) with the proviso, however, that when (a) is a double bond, then W exclusively represents a CH or CCH₃ group, and that when (a) is a single bond, then W exclusively represents a CH₂, CHCH₃, C(CH₃)₂, C(CH₂)₂ or C(CH₂)₃ group;
- X is a carbon atom bearing a hydrogen atom (CH) or a nitrogen atom; and
- Y is a hydrogen atom or a fluorine atom;

~~their or an addition salts and optionally the hydrates of the addition salts salt or~~

hydrate thereof with a pharmaceutically acceptable inorganic acids acid or organic acids and their acid or a tautomeric forms form, the pure enantiomers and mixtures enantiomer or mixture of racemic or nonracemic enantiomers thereof.

2. (Currently Amended) The derivatives A compound as claimed in claim 1, characterized in that they are chosen from the following compounds which is:
[2-(2,2-dimethyl-2,3-dihydrobenzofuran-7-yloxy)ethyl]-(3-cyclopenten-1-ylbenzyl)amine;
[2-(benzofuran-7-yloxy)ethyl]-(3-cyclopenten-1-ylbenzyl)amine;
[2-(2-methylbenzofuran-7-yloxy)ethyl]-(3-cyclopenten-1-ylbenzyl)amine;
[2-(2,3-dihydrobenzofuran-7-yloxy)ethyl]-(3-cyclopenten-1-ylbenzyl)amine;
[2-(2-spirocyclopropyl-2,3-dihydrobenzofuran-7-yloxy)ethyl]-(3-cyclopenten-1-ylbenzyl)amine;
[2-(2,2-dimethyl-2,3-dihydrobenzofuran-7-yloxy)ethyl]-[3-(2-fluorocyclopenten-1-yl)benzyl]amine; or
[2-(2,2-dimethyl-2,3-dihydrobenzofuran-7-yloxy)ethyl]-(5-cyclopenten-1-ylpyridine-3-ylmethyl)amine;
their or an addition salts and optionally the hydrates salt or hydrate of said addition salts salt with a pharmaceutically acceptable inorganic acids acid or organic acids acid and their isomers and their tautomers or an isomer or tautomer thereof.

3. (Currently Amended) A compound of having the formula (2):



~~in which X and Y have the same meaning as in formula (1) as synthesis intermediate involved in the preparation of the compounds of formula (1) in which X is a carbon atom bearing a hydrogen atom (CH) or a nitrogen atom, and Y is a hydrogen atom or a fluorine atom.~~

4. (Cancelled)


5. (Currently Amended) ~~A pharmaceutical composition, characterized in that it contains comprising, as active ingredient, at least one compound as claimed in either of claims 1 and 2 combined with claim 1 and an inert pharmaceutical carrier or other pharmaceutically acceptable vehicles and vehicle, optionally with another medicament.~~

6. (Currently Amended) ~~The pharmaceutical composition as claimed in claim 5, which is useful in A method for the treatment of schizophrenia or useful in the treatment of the progression of schizophrenia comprising administering to an animal in need of such treatment an effective anti-psychotic amount of a composition as claimed in claim 5.~~

7. (New) A pharmaceutical composition comprising, as active ingredient, at least one compound as claimed in claim 2 and an inert pharmaceutical carrier or other pharmaceutically acceptable vehicle, optionally with another medicament.

8. (New) A method for the treatment of schizophrenia comprising administering to an animal in need of such treatment an effective anti-psychotic amount of a composition as claimed in claim 7.

9. (New) A process for the preparation of a compound having the formula (1) as claimed in claim 1, said process comprising reacting a compound having the formula (3) with a compound having the formula (2) according to the reaction scheme:



in which (a), W, X and Y are as defined in claim 1.